falsefalse

Data Updates in GI Cancers and HCC from ESMO 2024 - Episode 3

Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial

,

Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on data for neoadjuvant nivolumab plus ipilimumab in dMMR colon cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: 5-Year Follow-Up Data for Tremelimumab Plus Durvalumab in Unresectable HCC
    EP. 2: The STRIDE Regimen vs Atezolizumab/Bevacizumab: Selecting a Treatment Regimen in Unresectable HCC
    Now Viewing
    EP. 3: Neoadjuvant Nivolumab Plus Ipilimumab in dMMR Colon Cancer: The NICHE-2 Trial
    EP. 4: Final OS Data for Pembrolizumab Plus Trastuzumab/Chemotherapy in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
    EP. 5: Findings from the DESTINY-Gastric03 Trial in Advanced HER2+ Esophageal, Gastric, and GEJ Cancer
    EP. 6: Building Upon Approved Combination Regimens in Unresectable HCC
    EP. 7: Ongoing Research in GI Cancers

    Related Content:

    Data Updates in GI Cancers and HCC from ESMO 2024Karmanos Cancer InstituteColorectal CancerOncLive News Network®
    FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications
    Dr Bando on Safety of TAS-102 in MRD+ Resected CRC
    FDA Approves Nivolumab Plus Ipilimumab for dMMR/MSI-H Metastatic CRC
    x